Patents by Inventor Lhanoo Gunawardhana

Lhanoo Gunawardhana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS
    Publication number: 20180311217
    Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.
    Type: Application
    Filed: December 1, 2017
    Publication date: November 1, 2018
    Applicants: Takeda Pharmaceuticals U.S.A., Inc., Teijin Pharma Limied
    Inventors: Lhanoo Gunawardhana, Vijay Gupte, Himanshu Naik, Michael Mayer, Kanji Komatsu
  • Methods for concomitant treatment of theophylline and febuxostat
    Patent number: 9107912
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 18, 2015
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS
    Publication number: 20140357683
    Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Inventors: Lhanoo Gunawardhana, Vijay Gupte, Himanshu Naik, Michael Mayer, Kanji Komatsu
  • Methods for concomitant treatment of theophylline and febuxostat
    Patent number: 8372872
    Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: February 12, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Lhanoo Gunawardhana, Himanshu Naik, Max Tsai
  • METHODS FOR STABILIZING JOINT DAMAGE IN SUBJECTS USING XANTHINE OXIDOREDUCTASE INHIBITORS
    Publication number: 20130012553
    Abstract: The present invention relates to methods for preventing the progression of joint damage in a subject having hyper-uricemia and who has gout thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. Moreover, the present invention also relates to methods of preventing joint damage in a subject having hyperuricemia and who has gout by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
    Type: Application
    Filed: February 18, 2011
    Publication date: January 10, 2013
    Inventors: Patricia MacDonald, Lhanoo Gunawardhana
  • METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT
    Publication number: 20120065215
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: November 14, 2011
    Publication date: March 15, 2012
    Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT
    Publication number: 20120065236
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: September 8, 2011
    Publication date: March 15, 2012
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik
  • METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT
    Publication number: 20120065207
    Abstract: The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
    Type: Application
    Filed: October 27, 2011
    Publication date: March 15, 2012
    Applicant: Takeda Pharmaceuticals North America, Inc.
    Inventors: Lhanoo Gunawardhana, Max Tsai, Himanshu Naik